What is the official website of IntrinsiQ Specialty Solutions ?

The official website of IntrinsiQ Specialty Solutions is http://www.intrinsiq.com.

What is IntrinsiQ Specialty Solutions's cybersecurity risk score?

IntrinsiQ Specialty Solutions has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has IntrinsiQ Specialty Solutions experienced?

According to Rankiteo, IntrinsiQ Specialty Solutions currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has IntrinsiQ Specialty Solutions been affected by any supply chain cyber incidents ?

According to Rankiteo, IntrinsiQ Specialty Solutions has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does IntrinsiQ Specialty Solutions have SOC 2 Type 1 certification ?

According to Rankiteo, IntrinsiQ Specialty Solutions is not certified under SOC 2 Type 1.

Does IntrinsiQ Specialty Solutions have SOC 2 Type 2 certification ?

According to Rankiteo, IntrinsiQ Specialty Solutions does not hold a SOC 2 Type 2 certification.

Does IntrinsiQ Specialty Solutions comply with GDPR ?

According to Rankiteo, IntrinsiQ Specialty Solutions is not listed as GDPR compliant.

Does IntrinsiQ Specialty Solutions have PCI DSS certification ?

According to Rankiteo, IntrinsiQ Specialty Solutions does not currently maintain PCI DSS compliance.

Does IntrinsiQ Specialty Solutions comply with HIPAA ?

According to Rankiteo, IntrinsiQ Specialty Solutions is not compliant with HIPAA regulations.

Does IntrinsiQ Specialty Solutions have ISO 27001 certification ?

According to Rankiteo,IntrinsiQ Specialty Solutions is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does IntrinsiQ Specialty Solutions operate in ?

IntrinsiQ Specialty Solutions operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does IntrinsiQ Specialty Solutions have ?

IntrinsiQ Specialty Solutions employs approximately 92 people worldwide.

Does IntrinsiQ Specialty Solutions own any subsidiaries ?

IntrinsiQ Specialty Solutions presently has no subsidiaries across any sectors.

How many LinkedIn followers does IntrinsiQ Specialty Solutions have ?

IntrinsiQ Specialty Solutions's official LinkedIn profile has approximately 2,353 followers.

What is the NAICS classification code for IntrinsiQ Specialty Solutions ?

IntrinsiQ Specialty Solutions is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does IntrinsiQ Specialty Solutions have a Crunchbase profile ?

No, IntrinsiQ Specialty Solutions does not have a profile on Crunchbase.

Does IntrinsiQ Specialty Solutions have a LinkedIn profile ?

Yes, IntrinsiQ Specialty Solutions maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/intrinsiq-llc.

How many cybersecurity incidents has IntrinsiQ Specialty Solutions experienced ?

As of September 22, 2026, Rankiteo reports that IntrinsiQ Specialty Solutions has experienced 11 cybersecurity incidents.

How many peer or competitor companies does IntrinsiQ Specialty Solutions have ?

IntrinsiQ Specialty Solutions has an estimated 5,770 peer or competitor companies worldwide.

What types of cybersecurity incidents has IntrinsiQ Specialty Solutions faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

ISS

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

IntrinsiQ Specialty Solutions Vendor Cyber Rating & Cyber Score

intrinsiq.com

Add Your Compliance Badge

IntrinsiQ Specialty Solutions, a part of Cencora, is the leading provider of electronic health records, practice financial management solutions, and pharmaceutical analytics in the independent physician specialty market. They provide software solutions to over 6,000 specialty physicians across the United States and provide analytic solutions to life sciences companies within the specialty drug market. For analytics solutions for life sciences, visit intrinsiqanalytics.com. For software solutions, services or clinical and business intelligence for providers visit intrinsiq.com. IntrinsiQ Specialty Solutions is part of the Cencora family of companies. Cencora, previously known as AmerisourceBergen, is a leading global pharmaceutical

ISS

IntrinsiQ Specialty Solutions CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

IntrinsiQ Specialty...

Breach

100

9/2025

AME476204709202...

Cencora

Breach

100

1/2025

INOCEN177580230...

IntrinsiQ Specialty...

Breach

11/2024

WOR100072725

IntrinsiQ Specialty...

Breach

100

9/2024

MWI630072625

IntrinsiQ Specialty...

Breach

8/2024

AME345072925

IntrinsiQ Specialty...

Breach

4/2024

AME425072825

IntrinsiQ Specialty...

Breach

2/2024

MWI122072925

IntrinsiQ Specialty...

Breach

2/2024

AME453224509302...

IntrinsiQ Specialty...

Breach

2/2024

CEN270212709302...

IntrinsiQ Specialty...

Cyber Attack

03/2023

ALL363723

IntrinsiQ Specialty...

Breach

02/2023

AME62016223

Loading…

A.I.

ISS Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for ISS

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for IntrinsiQ Specialty Solutions in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for IntrinsiQ Specialty Solutions in 2026.

Incident Types ISS vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for IntrinsiQ Specialty Solutions in 2026.

Incident History - ISS (X = Date, Y = Severity)

Loading…

SUBSIDIARY

IntrinsiQ Specialty Solutions Subsidiaries

ISS

Pharmaceutical Manufacturing

Website: http://www.intrinsiq.com

Company Size: 92

CencoraHospitals and Health Care

AmerisourceBergenHospitals and Health Care

Innomar StrategiesPharmaceutical Manufacturing

American Health PackagingPharmaceutical Manufacturing

MWI Animal HealthVeterinary Services

ION Oncology Practice NetworkPharmaceutical Manufacturing

ASD HealthcarePharmaceutical Manufacturing

ICSPharmaceutical Manufacturing

US BioservicesPharmaceutical Manufacturing

Besse MedicalPharmaceutical Manufacturing

Alliance HealthcarePharmaceutical Manufacturing

World CourierTransportation, Logistics, Supply Chain and Storage

Triose, Inc.Transportation, Logistics, Supply Chain and Storage

Loading…

IntrinsiQ Specialty Solutions Similar Companies

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Loading…

NEWS

IntrinsiQ Specialty Solutions CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

October 16, 2025 07:00 AM

Oncology biomarker data fuels precision care — IntrinsiQ expands insights across oncology, retina, specialty

IntrinsiQ (Cencora) adds oncology biomarker data plus expanded retina and therapeutic-area insights to enable precision medicine,...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-94426

SUMMARY

A vulnerability was determined in xuxueli xxl-job up to 3.5.0. The impacted element is an unknown function of the file /jobgroup/insert. This manipulation of the argument Name causes cross site scripting. The attack can be initiated remotely. The exploit has been publicly disclosed and may be utilized. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-21

Updated

Date2026-09-21

RISK INFORMATION (Score: 3.5)

cvss2

Base Score: 4.0

Complexity: LOW

AV:N/AC:L/Au:S/C:N/I:P/A:N

cvss3

Base Score: 3.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:N/I:L/A:N

cvss4

Base Score: 2.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.1

REFERENCES

CVE-2026-94425

SUMMARY

A vulnerability was found in Moore Threads MTT S80 Driver Package 340.150. The affected element is the function sub_140006F0C in the library mtdispkm64.sys of the component IOCTL Handler. The manipulation results in improper privilege management. Attacking locally is a requirement. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-21

Updated

Date2026-09-21

RISK INFORMATION (Score: 8.8)

cvss2

Base Score: 6.8

Complexity: LOW

AV:L/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-94627

SUMMARY

vLLM Mooncake connector through 0.29.0 fails to properly manage GPU KV cache block ownership when concurrent child requests share a single transfer ID in prefill/decode disaggregated deployments. Attackers can trigger GPU memory exhaustion by submitting completion requests with multiple prompts, causing orphaned KV cache blocks to accumulate until process restart and eventually preventing legitimate requests from executing.

Published

Date2026-09-21

Updated

Date2026-09-21

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-94626

SUMMARY

vLLM through 0.29.0 fails to validate the tp_size parameter in kv_transfer_params on OpenAI-compatible completion endpoints, allowing attackers to allocate unbounded memory. Attackers can supply arbitrary tp_size values in prefill/decode disaggregated deployments to exhaust memory and trigger kernel OOM-kill of the decode worker process.

Published

Date2026-09-21

Updated

Date2026-09-21

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-94625

SUMMARY

vLLM through 0.29.0 contains a resource exhaustion vulnerability in MooncakeConnector where rejected prefill requests create ownerless transfer placeholders that are never reclaimed. Attackers can send rejected requests to exhaust sender task pools, causing valid requests to be delayed by up to 480 seconds while health checks continue returning success.

Published

Date2026-09-21

Updated

Date2026-09-21

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

IntrinsiQ Specialty Solutions Vendor Cyber Rating & Cyber Score

ISS A.I CyberSecurity Scoring

IntrinsiQ Specialty Solutions CyberSecurity News & History

ISS Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for ISS

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types ISS vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - ISS (X = Date, Y = Severity)

IntrinsiQ Specialty Solutions Subsidiaries

ISS

IntrinsiQ Specialty Solutions Similar Companies

Grifols

Catalent

Cipla

AUROBINDO PHARMA LTD

Bristol Myers Squibb

Viatris

PT Kalbe Farma, Tbk

Astellas Pharma

Teva Pharmaceuticals

IntrinsiQ Specialty Solutions CyberSecurity News

Oncology biomarker data fuels precision care — IntrinsiQ expands insights across oncology, retina, specialty

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

IntrinsiQ Specialty Solutions CyberSecurity News & History

ISS Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for ISS

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types ISS vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - ISS (X = Date, Y = Severity)

IntrinsiQ Specialty Solutions Subsidiaries

ISS

IntrinsiQ Specialty Solutions Similar Companies

Grifols

Catalent

Cipla

AUROBINDO PHARMA LTD

Bristol Myers Squibb

Viatris

PT Kalbe Farma, Tbk

Astellas Pharma

Teva Pharmaceuticals

IntrinsiQ Specialty Solutions CyberSecurity News

Oncology biomarker data fuels precision care — IntrinsiQ expands insights across oncology, retina, specialty

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo